MX2018016417A - Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas. - Google Patents

Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas.

Info

Publication number
MX2018016417A
MX2018016417A MX2018016417A MX2018016417A MX2018016417A MX 2018016417 A MX2018016417 A MX 2018016417A MX 2018016417 A MX2018016417 A MX 2018016417A MX 2018016417 A MX2018016417 A MX 2018016417A MX 2018016417 A MX2018016417 A MX 2018016417A
Authority
MX
Mexico
Prior art keywords
tatä
cdkl5
fusion proteins
compositions
formulations
Prior art date
Application number
MX2018016417A
Other languages
English (en)
Inventor
Ciani Elisabetta
Laccone Franco
clark Sean
Original Assignee
Univ Bologna Alma Mater Studiorum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater Studiorum filed Critical Univ Bologna Alma Mater Studiorum
Publication of MX2018016417A publication Critical patent/MX2018016417A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11023—[RNA-polymerase-subunit] kinase (2.7.11.23)

Abstract

En el presente documento se describen composiciones y formulaciones que contienen una proteína de fusión TATK-CDKL5. También se desvelan métodos de producción de una proteína de fusión TATK-CDKL5 de vectores que contienen un ADNc de TATK-CDKL5 y métodos de transducción de células con los vectores que contienen un ADNc de TATK-CDKL5 y la proteína de fusión TATK-CDKL5. También se desvelan los usos de las proteínas de fusión TATK-CDKL5 para tratar deficiencias en CDKL5 por administración sistémica o intravenosa de las proteínas de fusión.
MX2018016417A 2016-06-28 2017-06-28 Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas. MX2018016417A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355579P 2016-06-28 2016-06-28
US201662381886P 2016-08-31 2016-08-31
PCT/US2017/039692 WO2018005617A2 (en) 2016-06-28 2017-06-28 TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF

Publications (1)

Publication Number Publication Date
MX2018016417A true MX2018016417A (es) 2019-09-09

Family

ID=60787683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016417A MX2018016417A (es) 2016-06-28 2017-06-28 Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas.

Country Status (12)

Country Link
US (1) US20210268072A1 (es)
EP (1) EP3475418A4 (es)
JP (1) JP2019522989A (es)
KR (1) KR20190034546A (es)
CN (1) CN109844109A (es)
AU (1) AU2017290047A1 (es)
BR (1) BR112018077225A2 (es)
CA (1) CA3029473A1 (es)
IL (1) IL263842A (es)
MX (1) MX2018016417A (es)
TW (1) TW201803893A (es)
WO (1) WO2018005617A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
CN114901802A (zh) * 2019-10-30 2022-08-12 阿米库斯治疗学公司 重组cdkl5蛋白、基因疗法和生产方法
IL303239A (en) 2020-12-01 2023-07-01 Univ Pennsylvania Compositions and their uses for the treatment of Engelmann syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100489101C (zh) * 2006-12-19 2009-05-20 浙江大学 G-eGFP蛋白及其制备方法与应用
CN101704893A (zh) * 2009-11-02 2010-05-12 江苏大学 带穿膜序列的人Scurfin蛋白全长及片段以及制备方法
AU2015221860B2 (en) * 2014-02-28 2019-09-12 Alma Mater Studiorum-Universita Di Bologna TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
WO2017153834A1 (en) * 2016-03-10 2017-09-14 Alma Mater Studiorum - Universitá Di Bologna TREATMENT OF CDKL5 DISORDERS WITH GSK3β INHIBITOR TIDEGLUSIB

Also Published As

Publication number Publication date
TW201803893A (zh) 2018-02-01
AU2017290047A1 (en) 2019-01-17
EP3475418A4 (en) 2020-03-04
JP2019522989A (ja) 2019-08-22
CN109844109A (zh) 2019-06-04
US20210268072A1 (en) 2021-09-02
WO2018005617A2 (en) 2018-01-04
WO2018005617A3 (en) 2018-02-08
KR20190034546A (ko) 2019-04-02
IL263842A (en) 2019-01-31
BR112018077225A2 (pt) 2019-04-09
EP3475418A2 (en) 2019-05-01
CA3029473A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
BR112018012145A2 (pt) partículas de entrega de pró-sabor
SG10201803042PA (en) Anti-tim-3 antibodies
WO2018109174A3 (en) Il-11 antibodies
MY195442A (en) Anti-CD40 Antibodies and Their Uses
WO2015048348A3 (en) Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof
SG10201806693XA (en) Anti-myostatin antibodies and methods of use
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
NZ721607A (en) Fusion protein inhibiting angiogenesis or growth and use thereof
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2020006635A (es) Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma.
MX2018016417A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas.
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
WO2018202921A3 (en) Nanostructured proteins and uses thereof
AU2018276376A1 (en) Cell culture methods
EP3337526A4 (en) AZELLULAR HORN SKIN, METHOD FOR THE MANUFACTURE THEREOF AND USES THEREOF
PH12019501765A1 (en) Factor ix fusion proteins and methods of making and using same
WO2015143240A3 (en) Compositions and methods comprising 2-(acylamino)imidazoles
WO2018013551A8 (en) Tools for next generation komagataella (pichia) engineering
WO2016176440A3 (en) Thrombin-thrombomodulin fusion proteins as protein c activators